Introduction {#s1}
============

Vitamin D plays a key role in human health, while the prevalence of vitamin D insufficiency is high, especially among the elderly \[[@B1]\]. It has recently been identified to be associated with skeletal diseases such as osteoporosis \[[@B2]\] and non-skeletal diseases including cancer \[[@B3]-[@B5]\], cardiovascular disease \[[@B6]\], and kidney disease \[[@B7],[@B8]\]. Meta-analysis has suggested that low vitamin D baseline levels are associated with increased risks of mortality \[[@B9]\]. This issue is becoming to be paramount importance given the high prevalence of vitamin D deficiency worldwide \[[@B10]\].

It has been documented that vitamin D supplementation prevents fractures and falls \[[@B11],[@B12]\]. In recent years, several studies on meta-analysis of randomized controlled trials with regard to supplementation of vitamin D on total mortality have been published, which found that vitamin D supplementation reduced total mortality when given together with calcium, but not with vitamin D alone \[[@B13]-[@B16]\], and. A Cochrane systematic review found that vitamin D significantly decreased mortality in those with vitamin D insufficiency \[[@B15]\]. However, long-term health effects of vitamin D supplementation still remains unclear.

To investigate whether the effects of vitamin D supplementation on all-cause mortality are associated with duration of treatment, we undertook a comprehensive systematic database search and meta-analysis to access the effects of vitamin D supplementation on all-cause mortality.

Materials and Methods {#s2}
=====================

Search strategy {#s2.1}
---------------

A literature search was conducted on a number of databases, including Medline, Embase and The Cochrane Central Register of Controlled Trials for the period January 1960 to January 2013, to identify RCTs. Our core search terms were "randomized controlled trial", "vitamin D", "vitamin D~2~", "vitamin D~3~", "ergocalciferol", "cholecalciferol", "mortality", "death". We also searched for any additional studies in the reference lists of recent meta-analysis of vitamin D treatment for mortality. Our searches were limited to human trials, and no language or time restriction was applied.

Eligibility criteria {#s2.2}
--------------------

The preliminary search results were then examed on the basis of the following criteria.

### Types of studies {#s2.2.1}

Randomized controlled trials evaluating an intervention with vitamin D were identified as part of the review, while review articles, commentaries, letters, observational studies were excluded.

### Interventions {#s2.2.2}

The intervention group was restricted to vitamin D alone or in combination with calcium treatment; the control group was placebo, no treatment or calcium only therapy. Studies of patients receiving active vitamin D and intramuscular injection of vitamin D were excluded from the review.

### Outcome {#s2.2.3}

The number of deaths was reported separately for the vitamin D treatment group and the control group. For articles with a large sample size, if the number of deaths was not reported by treatment, we tried to contact the authors to obtain the missing data.

Data Extraction and Quality Assessment {#s2.3}
--------------------------------------

Two statisticians independently extracted information from included trials using a standardized form., and then another statisticians verified them. The following information was subtracted from the study: first author, publishing year, sample size, duration, dwelling, intervention, serum 25 (OH) D levels at baseline, and main results (the number of participants who died). Quality assessment of included trials was conducted using the Cochrane Collaboration's tool \[[@B17]\]. Methodological features most relevant to the control of bias were examined, including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias \[[@B17]\]. Quality assessment was performed by two independent researchers.

Data Synthesis and Analysis {#s2.4}
---------------------------

Meta-analysis were undertaken using Review Manager (Version 5.0). The primary outcome was the number of participants who died during follow-up. The pre-planned analysis was vitamin D arm (with or without calcium) versus control arm (placebo, calcium, or no treatment) according to duration of treatment. Mantel-Haenszel method was used to calculate risk ratios (RRs) and their 95% confidence intervals (CI). The I^2^ statistic was used to assess the presence of heterogeneity, which ranges from 0% to 100% \[[@B18]\]. In case of lack of heterogeneity (I^2^ \< 50%), fixed-effects model was used to assess the overall estimate, or else random-effects model was chosen. The Begg test \[[@B19]\] and Egger test \[[@B20]\] were used to evaluate the presence of publication bias regarding our primary end points (RR of mortality). A 2-tailed *P* value of less than .05 was considered as statistically significant.

Sensitivity analysis and subgroup analysis {#s2.5}
------------------------------------------

A sensitivity analysis was conducted by excluding studies with high risk of bias. Subgroup analysis was conducted only on trials with the duration of treatment at least 3 years or longer. The effect of vitamin D was assessed according to gender (male or female), age group (\< 80 years or ≥ 80 years), dose of oral vitamin D daily (≤800 IU or \>800 IU), baseline level of 25- hydroxyvitamin D (\< 50 nmol per liter or ≥ 50 nmol per liter), type of vitamin D (ergocalciferol or cholecalciferol) and calcium co-administration status (Vitamin D + calcium vs. Calcium, Vitamin D + calcium vs. Placebo, or Vitamin D vs. Placebo), and specific mortality (cancer mortality, cardiovascular mortality)

Results {#s3}
=======

Search Results {#s3.1}
--------------

A total of 4,024 unique titles and abstracts were found from initial searches of the electronic database. With the inclusion/exclusion criteria, 3,861 of which were excluded by scrutinizing the titles and abstracts, and 121 articles were further excluded after full text review. A total of 42 RCTs that met inclusion criteria were included in the final analysis \[[@B21]-[@B62]\]. The details of study selection flow were explicitly described in [Figure 1](#pone-0082109-g001){ref-type="fig"}.

![Study flow diagram.](pone.0082109.g001){#pone-0082109-g001}

Study Characteristics {#s3.2}
---------------------

The main characteristics of the included studies are shown in Table 1 (1). Publishing year: The RCTs were published from 1992 to 2012 (2). Treatment duration: 29 RCTs have treatment durations less than 3 years, and the remaining 13 RCTs have treatment durations of 3 years or longer (3). Number of patients: A total of 85,466 patients (42,561 in the vitamin D group and 42,905 in the control group) were included in these 42 RCTs (4). Age of patients: The number of participants in each trial ranged from 46 to 36,282 and mean age of participants ranged from 37 to 89 years, with most participants older than 60 years (5). Vitamin D type and dose: Vitamin D~2~ was used in 10 studies and vitamin D~3~ was used in the remaining 32 studies. Vitamin D~2~ or D~3~ was given as daily doses ranging from 300 to 3,333 IU. Calcium supplementation was used in 26 trials (6). Baseline vitamin D status: 37 trials (80%) reported the baseline vitamin D status of participants based on serum 25-hydroxyvitamin D levels. Participants in 15 trials had baseline 25-hydroxyvitamin D levels at or above cutoff for vitamin D adequacy (50 nmol/l or 20 ng/ml). Participants in the remaining 22 trials had baseline 25-hydroxyvitamin D levels in a range of vitamin D insufficiency (\< 50 nmol/l or 20 ng/ml). The other 5 trials did not report the baseline vitamin D status of participants (7). Bias risk: 26 studies had a low risk of bias, and 16 had a high risk of bias (Table 2).

10.1371/journal.pone.0082109.t001

###### Characteristics of the included studies.

  Study                                          Population characteristics                                               Treatment groups                                                                                                     Number of participants   Mean age (years)   Baseline Serum 25 (OH) D levels (mmol/l; mean)   Follow up
  ---------------------------------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------- ------------------------ ------------------ ------------------------------------------------ ------------
  Trials have a follow-up of 3 years or longer                                                                                                                                                                                                                                                                                              
  Avenell 2012                                   Community dwelling, with past low-energy racture                         Vit D~3~ 800 IU daily                                                                                                1343                     77                 38                                               5-8 years
                                                                                                                          Vit D~3~ 800 IU daily + Ca1000 mg daily                                                                              1306                     77                 38                                               
                                                                                                                          Ca 1000 mg daily                                                                                                     1311                     78                 38                                               
                                                                                                                          Placebo                                                                                                              1332                     77                 38                                               
  Bolland 2011                                   Community-based postmenopausal women                                     Vit D~3~ 400 IU daily + Ca 1000 mg daily                                                                             18176                    62                 46                                               7 years
                                                                                                                          Placebo                                                                                                              18106                    62                 48                                               
  Sanders 2010                                   Ambulatory elderly women at risk for fracture                            Vit D~3~ 5000000 IU annually for 3-5 year                                                                            1131                     77                 53                                               3 years
                                                                                                                          Placebo                                                                                                              1125                     77                 45                                               
  Salovaara 2010                                 Women aged 65--71 years                                                  Vit D~3~ 800 IU daily + Ca 1000 mg daily                                                                             1586                     67                 50                                               3 years
                                                                                                                          No treatment                                                                                                         1609                     67                 49                                               
  Zhu 2008                                       Community-dwelling women aged 70--80 year                                Vit D~2~ 1000 IU daily + Ca 1200 mg daily                                                                            39                       75.4               70.2                                             5 years
                                                                                                                          Ca 1200 mg daily                                                                                                     40                       74.1               66.6                                             
                                                                                                                          Placebo                                                                                                              41                       74.8               67.3                                             
  Lappe 2007                                     Healthy postmenopausal white women                                       Vit D~2~ 1100 IU + Ca 1400-1500 mg daily                                                                             446                      66.7               71.8                                             4 years
                                                                                                                          Ca 1400-1500 mg daily                                                                                                445                      66.7               71.6                                             
                                                                                                                          Placebo                                                                                                              288                      66.7               72.1                                             
  Lyons 2007                                     Nursing home residents                                                   Initially 100000 IU Vit D~2~ weekly, then 1000 IU Vit D~2~ daily + Ca 600 mg daily                                   1725                     84                 80                                               3 years
                                                                                                                          Ca 600 mg daily                                                                                                      1715                     84                 54                                               
  Aloia 2005                                     Healthy black postmenopausal women                                       Vit D~3~ 800 IU daily + Ca 1200 to 1500 mg daily (after 2 years 2000 IU daily)                                       104                      59.9               48.25                                            3 years
                                                                                                                          Ca 1200 to 1500 mg daily                                                                                             104                      61.2               43                                               
  Larsen 2004                                    Community-dwelling residents                                             Vit D~3~ 400 IU daily + Ca 1000 mg daily                                                                             4957                     75                 37                                               42 months
                                                                                                                          No treatment                                                                                                         4648                     75                 33                                               
  Trivedi 2003                                   Community dwelling individuals                                           VitD~3~ 100000 IU every 4 months                                                                                     1345                     75                 74                                               5 years
                                                                                                                          Placebo                                                                                                              1341                     75                 53                                               
  Komulainen 1999                                Nonosteoporotic, early postmenopausal                                    Vit D~3~ 300 IU daily (no intake during June-August) for 4 years and 100 IU daily in the5th year + Ca 500 mg daily   112                      52.9               NA                                               5 yeas
                                                                                                                          Placebo                                                                                                              115                      52.6               NA                                               
  D-Hughes 1997                                  Healthy, ambulatory eldely older than 65 years                           Vit D~3~ 700 IU daily + Ca 500 mg daily                                                                              187                      71                 71.75                                            3 years
                                                                                                                          Placebo                                                                                                              202                      72                 61.25                                            
  Lips 1996                                      Elderly living in apartments or homes                                    VitD~3~ 400 IU daily                                                                                                 1291                     80                 27                                               3.5 years
                                                                                                                          Placebo                                                                                                              1287                     80                 26                                               
  Trials have a follow-up of less than 3 years                                                                                                                                                                                                                                                                                              
  Alvarez 2012                                   Patients with early chronic kidney disease                               Vit D 50000 IU weekly for one year                                                                                   22                       62.3               26.7                                             1 year
                                                                                                                          Placebo                                                                                                              24                       62.6               32.1                                             
  Lehouck 2012                                   chronic obstructive pulmonary disease                                    Vit D~3~ 100000 IU every 4 months for one year                                                                       91                       68                 50                                               1 year
                                                                                                                          Placebo                                                                                                              91                       68                 50                                               
  TiIDE trial 2012                               Patients with type 2 diabetes                                            Vit D~3~ 1000 IU daily foe one year                                                                                  607                      66.7               NA                                               6 months
                                                                                                                          Placebo                                                                                                              614                      66.6               NA                                               
  Wasse 2012                                     Patients with hemodialysis                                               Vit D~3~ 200000 IU weekly for 3 weeks                                                                                25                       49                 35.8                                             53 days
                                                                                                                          No treatment                                                                                                         27                       52                 47.5                                             
  Witham 2010                                    Older patients with heart failure                                        Vit D~2~ 100000 IU at 0 and 10 week                                                                                  53                       78.8               20.5                                             20 weeks
                                                                                                                          Placebo                                                                                                              52                       80.6               23.7                                             
  Lips 2010                                      Elderly with vitamin D insufficient                                      Vit D~3~ 8400 IU weekly for 3 weeks                                                                                  114                      78.5               34.3                                             16 weeks
                                                                                                                          Placebo                                                                                                              112                      77.6               35.3                                             
  Wejse 2009                                     Patients with tuberculosis                                               Vit D~3~ 100000 IU at 0, 5, 8 month                                                                                  187                      37                 77.5                                             1 year
                                                                                                                          Placebo                                                                                                              180                      38                 79.1                                             
  Chel 2008                                      Nursing home residents                                                   Vit D~3~ 600 IU daily, or 4200 IU weekly or 180000 IU monthly for 4.5 month                                          166                      84.2               24.9                                             4.5 months
                                                                                                                          Placebo                                                                                                              172                      84.2               25.0                                             
  Bjorkman 2008                                  Aged chronically immobile patients                                       Vit D~3~ 1200 IU daily                                                                                               73                       83.9               24                                               6 months
                                                                                                                          Vit D~3~ 400 IU daily                                                                                                77                       84.2               21                                               
                                                                                                                          Placebo                                                                                                              68                       85.6               23                                               
  Prince 2008                                    Recruited from emergency department or nursing home                      Vit D~2~ 1000 IU daily + Ca 1000 daily                                                                               151                      77                 45                                               1 year
                                                                                                                          Ca 1000 daily                                                                                                        151                      77                 44                                               
  Burleigh 2007                                  Rehabilitation wards in an acute geriatric unit                          Vit D~3~ 800 IU daily + Ca 1200 daily                                                                                101                      82                 22                                               1 year
                                                                                                                          Ca 1200 daily                                                                                                        104                      84                 25                                               
  Bolton-Smith 2007                              Healthy older women                                                      Vit D~3~ 400 IU daily + Ca1000 daily                                                                                 62                       69.4               62.5                                             2 years
                                                                                                                          Placebo                                                                                                              61                       67.8               57                                               
  Broe 2007                                      Nursing home residents                                                   Vit D~2~ 200-800 IU daily                                                                                            99                       89                 48.75                                            5 months
                                                                                                                          Placebo                                                                                                              25                       86                 50                                               
  Law 2006                                       Nursing home residents                                                   Vit D~2~ 100000 IU/3 months                                                                                          1762                     85                 59                                               10 months
                                                                                                                          Placebo                                                                                                              1955                     85                 59                                               
  Schleithoff 2006                               Patients with congestive heart failure                                   Vita D~3~ 2000 IU daily + Ca 500 daily for 9 month                                                                   61                       57                 36                                               15 months
                                                                                                                          Ca 500 daily                                                                                                         62                       54                 38                                               
  Brazier 2005                                   Ambulatory women aged \> 65 years with vitamin D insufficiency           Vit D~3~ 800 IU daily + Ca 1000 daily                                                                                95                       74.2               18.25                                            1 year
                                                                                                                          Placebo                                                                                                              97                       75                 17.5                                             
  Flicker 2005                                   Institutionalized with vitamin D level between 25 and 90 nmol/l          Vit D~3~ initially 100000 IUweekly, then 1000 IU daily + Ca 600 mg daily                                             313                      84                 25-90                                            2 years
                                                                                                                          Ca 600 mg daily                                                                                                      312                      83                 25-90                                            
  Porthouse 2005                                 Women aged 70 or over with risk factors for hip fracture                 Vit D~3~ 800 IU daily + Ca1000 daily                                                                                 1321                     77                 NA                                               25 months
                                                                                                                          Leaflet                                                                                                              1993                     76.7               NA                                               
  Avenell 2004                                   Participants had had an osteoporotic fracture within the last 10 years   Vit D~3~ 800 IU daily + Ca1000 daily                                                                                 99                       77                 NA                                               1 year
                                                                                                                          No treatment                                                                                                         35                       75.6               NA                                               
  Harwood 2004                                   Elderly women after hip fracture                                         Vit D~3~ 800 IU+ Ca 1000 mg daily                                                                                    29                       83                 29                                               1 year
                                                                                                                          No treatment                                                                                                         35                       81                 30                                               
  Meier 2004                                     Healthy adults                                                           VitD~3~ 500 IU+ Ca 500 mg daily                                                                                      30                       55.2               75.25                                            1.5 years
                                                                                                                          No treatment                                                                                                         25                       57.9               77                                               
  Cooper 2003                                    Women who were ≥ 1 y postmenopausal                                      Vit D~2~ 100000 IU weekly + Ca 1000 daily                                                                            93                       56.5               81.6                                             2 years
                                                                                                                          Ca 1000 daily                                                                                                        94                       56.1               82.6                                             
  Latham 2003                                    Recruited from geriatric rehabilitation center                           Vit D~2~ 300,000 IU/im/once                                                                                          108                      80                 38                                               6 months
                                                                                                                          Placebo                                                                                                              114                      79                 48                                               
  Meyer 2002                                     Nursing home residents                                                   Vit D~3~ 400 IU daily                                                                                                569                      84                 47                                               2 years
                                                                                                                          Placebo                                                                                                              575                      85                 51                                               
  Chapuy 2002                                    Elderly ambulatory institutionalized women                               Vit D~3~ 800 IU daily + Ca 1200 mg daily                                                                             393                      85                 22.5                                             2 years
                                                                                                                          Placebo                                                                                                              190                      85                 22.7                                             
  Krieg 1999                                     Elderly women living in nursing homes                                    Vit D~3~ 880 IU daily + Ca 1000 mg daily                                                                             124                      84                 29.8                                             2 years
                                                                                                                          No treatment                                                                                                         124                      85                 29.3                                             
  Bæksgaard 1998                                 Healthy postmenopausal women                                             Vit D~3~ 560 IU daily + Ca 1000 mg daily                                                                             80                       62.9               NA                                               2 years
                                                                                                                          No treatment                                                                                                         80                       61.8               NA                                               
  Ooms 1995                                      Elderly women                                                            VitD~3~ 400 IU daily                                                                                                 177                      80.1               27                                               2 years
                                                                                                                          Placebo                                                                                                              171                      80.6               25                                               
  Chapuy 1992                                    Elderly living in apartments or nursing homes                            Vit D~3~ 800 IU daily + Ca 1200 mg daily                                                                             1634                     84                 40                                               2 years
                                                                                                                          Placebo                                                                                                              1636                     84                 32.5                                             

Vit D, vitamin D; Ca, calcium

10.1371/journal.pone.0082109.t002

###### Quality assessment of the included studies.

  Study                                          Random sequence Generation (selection bias)   Allocation Concealment (selection bias)   Blinding of participants and personnel (performance bias)   Blinding of outcome assessment (detection bias)   Incomplete outcome data (attrition bias)   Selective reporting Reporting (reporting bias)   Other bias
  ---------------------------------------------- --------------------------------------------- ----------------------------------------- ----------------------------------------------------------- ------------------------------------------------- ------------------------------------------ ------------------------------------------------ ------------
  Trials have a follow-up of 3 years or longer                                                                                                                                                                                                                                                                                                     
  Avenell 2012                                   L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Bolland 2011                                   L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Sanders 2010                                   L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Salovaara 2010                                 L                                             L                                         H                                                           H                                                 L                                          L                                                L
  Zhu 2008                                       L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Lappe 2007                                     L                                             L                                         L                                                           L                                                 H                                          L                                                L
  Lyons 2007                                     L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Aloia 2005                                     L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Larsen 2004                                    U                                             H                                         H                                                           H                                                 H                                          U                                                H
  Trivedi 2003                                   L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Komulainen 1999                                L                                             L                                         L                                                           L                                                 L                                          L                                                L
  D-Hughes 1997                                  L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Lips 1996                                      L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Trials have a follow-up of less than 3 years                                                                                                                                                                                                                                                                                                     
  Alvarez 2012                                   L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Lehouck 2012                                   L                                             L                                         L                                                           L                                                 L                                          L                                                L
  TiIDE trial 2012                               L                                             U                                         U                                                           U                                                 L                                          L                                                H
  Wasse 2012                                     L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Witham 2010                                    L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Lips 2010                                      L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Wejse 2009                                     L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Chel 2008                                      U                                             U                                         U                                                           U                                                 L                                          L                                                L
  Bjorkman 2008                                  L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Prince 2008                                    L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Burleigh 2007                                  L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Boton-Smith 2007                               L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Broe 2007                                      L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Law 2006                                       L                                             H                                         H                                                           H                                                 L                                          L                                                U
  Schleithoff 2006                               L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Brazier 2005                                   L                                             U                                         U                                                           U                                                 L                                          L                                                H
  Flicker 2005                                   L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Porthouse 2005                                 L                                             L                                         H                                                           H                                                 L                                          U                                                H
  Avenell 2004                                   L                                             H                                         H                                                           H                                                 L                                          L                                                H
  Harwood 2004                                   L                                             L                                         H                                                           H                                                 L                                          L                                                H
  Meier 2004                                     U                                             U                                         H                                                           H                                                 L                                          L                                                U
  Cooper 2003                                    L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Latham 2003                                    L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Meyer 2002                                     H                                             H                                         L                                                           L                                                 L                                          L                                                H
  Chapuy 2002                                    U                                             U                                         U                                                           U                                                 L                                          L                                                H
  Krieg 1999                                     U                                             H                                         H                                                           H                                                 L                                          L                                                L
  Bæksgaard 1998                                 U                                             U                                         L                                                           L                                                 L                                          H                                                L
  Ooms 1995                                      L                                             L                                         L                                                           L                                                 L                                          L                                                L
  Chapuy 1992                                    U                                             U                                         U                                                           U                                                 L                                          L                                                L

Primary Analysis {#s3.3}
----------------

Analysis was performed independently for two categories with follow-up duration either less than 3 years, or 3 years or more. In the category of 29 trials with follow-up less than 3 years, a total of 1,175 (13.3%) participants randomized to the vitamin D group and 1,118 (12.2%) participants randomized to the placebo or no intervention group died. Analysis showed that vitamin D did not significantly decrease all-cause mortality. The risk ratio of mortality for patients treated with vitamin D compared with that of control was 1.04 (95% CI: 0.97--1.12), which was statistically insignificant (P = 0.28), with insignificant heterogeneity (I^2^ = 12%) ([Figure 2A](#pone-0082109-g002){ref-type="fig"}).

![Primary analysis (fixed effect model): A, studies under 3 years; B, studies over 3 years.](pone.0082109.g002){#pone-0082109-g002}

In the second category of 13 trials with follow-up of 3 years or longer, a total of 3,693 (10.9%) participants randomized to the vitamin D group and 3,880 (11.5%) participants randomized to the placebo or no intervention group died. Data analysis showed that vitamin D significantly decreased all-cause mortality with a risk ratio of mortality 0.94 (95% CI: 0.90--0.98), which was statistically significant (P = 0.001), with insignificant heterogeneity (I^2^ = 0%) ([Figure 2B](#pone-0082109-g002){ref-type="fig"}).

Sensitivity analysis {#s3.4}
--------------------

Sensitivity analysis was conducted by excluding the trials that had a high risk of bias, the results remain robust. For studies under 3 years (16 RCTs), the risk ratio of mortality for patients treated with vitamin D compared with control was 1.03 (95% CI: 0.86--1.24), which was not statistically significant (P = 0.72), with insignificant heterogeneity (I^2^ =0%) ([Figure 3A](#pone-0082109-g003){ref-type="fig"}). For studies over 3 years (10 RCTs), the risk ratio was 0.94 (95% CI: 0.90--0.98), which was statistically significant (P = 0.008), with insignificant heterogeneity (I^2^ =0%) ([Figure 3B](#pone-0082109-g003){ref-type="fig"}).

![Sensitivity analysis (fixed effect model): A, studies under 3 years; B, studies over 3 years.](pone.0082109.g003){#pone-0082109-g003}

Subgroup analysis of long-term follow-up studies {#s3.5}
------------------------------------------------

In subgroup analysis ([Table 3](#pone-0082109-t003){ref-type="table"}), significantly decreased mortality was seen in women (RR= 0.91; 95% CI: 0.83--1.00). Data on men were limited with only one related trial. Fewer death were found in patients younger than 80 years (RR= 0.93; 95% CI: 0.88--0.97), but not statistically significant in patients aged 80 years or older (RR= 0.97; 95% CI: 0.90--1.04). A dose of 800 IU or less (RR= 0.93; 95% CI: 0.89--0.98) was found to be more favorable than a dose greater than 800 IU (RR= 0.95; 95% CI: 0.89--1.03). Patients with baseline of 25-hydroxyvitamin D level less than 50 nmol/l treated with vitamin D resulted in significant reduction of mortality (RR= 0.93; 95% CI: 0.89--0.98), whereas no effect was seen in patients with baseline of 25-hydroxyvitamin D leve higher than 50 nmol/l (RR= 0.96; 95% CI: 0.89--1.03). Treatment with cholecalciferol (RR= 0.93; 95% CI: 0.89--0.97) was more favorable than with ergocalciferol (RR= 0.98; 95% CI: 0.90--1.06). Vitamin D combined with calcium was effective to reduce mortality when compared to placebo (RR= 0.94; 95% CI: 0.88--0.99), but not significantly effective when compared to calcium (risk ratio 0.97, 95% CI 0.91 to 1.03). The effect of vitamin D alone treatment was statistically insignificant compared to placebo (RR= 0.93; 95% CI: 0.86--1.00). Vitamin D treatment significantly reduced the cancer mortality (RR= 0.88; 95% CI: 0.79--0.98), but did not decrease cardiovascular mortality (RR= 0.91; 95% CI: 0.81--1.02).

10.1371/journal.pone.0082109.t003

###### Subgroup benefits at the longer duration of Vitamin D, as compared with control group (Trial level data).

  Subgroup                                                           No. of participants   No. of death   Risk ratio (95% CI)   P Value   I^2^, %                     
  ------------------------------------------------------------------ --------------------- -------------- --------------------- --------- ------------------- ------- ----
  Gender                                                                                                                                                              
  Male only                                                          1019                  1018           199                   220       0.88 (0.73--1.07)   0.19    0
  Female only                                                        22111                 22401          831                   919       0.91 (0.83--1.00)   0.04    0
  Age                                                                                                                                                                 
  \<80 yr                                                            30736                 30710          2698                  2859      0.93 (0.88--0.97)   0.002   0
  ≥80 yr                                                             3016                  3002           995                   1021      0.97 (0.90--1.04)   0.39    0
  Dose of oral vitamin D, IU                                         P=0.61                                                                                           
  ≤800                                                               29066                 28715          2712                  2851      0.93 (0.89--0.98)   0.003   0
  \>800                                                              4686                  4997           981                   1029      0.95 (0.89--1.03)   0.20    19
  Baseline 25-hydroxyvitamin D[\*](#ngtab3.1){ref-type="table-fn"}                                                                                                    
  \<50                                                               27177                 26788          2695                  2835      0.93 (0.89--0.98)   0.003   0
  ≥50                                                                6459                  6808           998                   1044      0.96 (0.89--1.03)   0.23    0
  Type of vitamin D                                                                                                                                                   
  Ergocalciferol                                                     2210                  2529           717                   735       0.98 (0.90--1.06)   0.59    45
  Cholecalciferol                                                    31542                 31183          2976                  3145      0.93 (0.89--0.97)   0.001   0
  Calcium coadministration status                                                                                                                                     
  Vitamin D + calcium *vs.* calcium                                  3174                  3170           1129                  1164      0.97 (0.91--1.03)   0.32    0
  Vitamin D + calcium *vs.* placebo                                  26367                 26054          2008                  2098      0.94 (0.88--0.99)   0.02    0
  Vitamin D *vs.* placebo                                            5110                  5087           967                   1034      0.93 (0.86--1.00)   0.06    0
  Specific mortality                                                                                                                                                  
  Cancer mortality                                                   22170                 22090          558                   632       0.88 (0.79--0.98)   0.03    0
  Cardiovascular mortality                                           22170                 22090          489                   537       0.91 (0.81--1.02)   0.11    0

Based on the reported mean baseline level, irrespective of type of vitamin D assay, in a sample of study participants

Publication bias {#s3.6}
----------------

No evidence of publication bias was detected for the risk ratio of mortality in this study by either Begg or Egger's test. For studies under 3 years, Begg's test P= 0.837, Egger's test P= 0.623; For studies over 3 years, Begg's test P= 0.059, Egger's test P= 0.055.

Discussion {#s4}
==========

We conducted a systematic review and meta-analysis to evaluate the best available research evidence regarding vitamin D supplementation on overall mortality. A total of 42 RCTs were included in the present study, quality assessment suggested that the overall study quality was fair and no significant publication bias was detected. Our results demonstrates that vitamin D supplementation longer than 3 years leads to a significant reduction on overall mortality. When trials with a high risk of bias excluded in the sensitive analysis, the results remain robust. The effect of vitamin D on mortality reduction was significant in several subgroups of individuals: female patients, participants with a mean age younger than 80, dose of 800 IU or less, participants with vitamin D insufficiency (baseline 25-hydroxyvitamin D level less than 50 nmol/L) and cholecalciferol therapy. In addition, compared with placebo, vitamin D in combination with calcium significantly reduced mortality.

Our findings confirmed those in an earlier Cochrane systematic review \[[@B15]\] on the effect of vitamin D treatment on overall mortality, which showed that participants with vitamin D insufficiency (25-hydroxyvitamin D level less than 20 ng/ml) decreased the overall mortality significantly, and indicated that cholecalciferol therapy was more favorable than ergocalciferol and that vitamin D as daily doses of 800 IU or less was more favorable than daily doses more than 800 IU. In contrast with two meta-analysis \[[@B13],[@B16]\], which compared daily dose of 800 IU or greater with that less than 800 IU and suggested that daily dose of vitamin D did not differ in the effect on the outcome, our analysis indicated that the beneficial effect of vitamin D is clearly observed in the low daily dose. One explanation may be that several included trials \[[@B23],[@B27],[@B30]\] used intermittent and high dose of vitamin D, which has been suggested less likely to have a benefit, or to even have a negative effect among the elderly \[[@B23]\]. Consumption of intermittent and high dose of vitamin D leads to high concentrations of plasma 25-hydroxyvitamin D. Michaëlsson et al \[[@B63]\] concluded that both high and low concentrations of plasma 25-hydroxyvitamin D were associated with elevated risks of overall and cancer mortality.

A previous meta-analysis conducted by Autier et al \[[@B13]\] suggested that no relationship was found with duration of vitamin D supplement. In contrast, our results indicated that vitamin D supplementation significantly reduced the overall mortality when duration was longer than 3 years compared with that of control. However, no benefit was seen in those with durations less than 3 years. Additionally, two meta-analyses of RCTs with vitamin D treatment on falls also reported that patients benefit from vitamin D supplementation in a longer time duration \[[@B64],[@B65]\].

Our results indicated that vitamin D was effective in reducing mortality among female patients. There was a lack of evidence to draw a conclusion of vitamin D's influence on male patients with only one identified trial collected death data by subgroup of gender. We concluded that vitamin D may decrease mortality in patients younger than 80 years old, but not in patients aged 80 years or older. However, no statistically significant difference was found for risk ratio of overall mortality between the two age groups (*P*= 0.59). This results support an early meta-analysis of vitamin D treatment on falls, which indicated that participants with a mean age younger than 80 benefited from vitamin D supplementation \[[@B64]\].

Several previous meta-analyses suggested that vitamin D supplementation reduced all-cause mortality when given together with calcium, but did not support an effect of vitamin D alone treatment \[[@B14]-[@B16]\]. In contrast, our results suggested that vitamin D combined with calcium reduced all-cause mortality significantly when compared with placebo (RR= 0.94; 95% CI: 0.88--0.99), but the effect was insignificantly when compared with calcium therapy (RR= 0.97; 95% CI: 0.91--1.03). Vitamin D alone had a trend to decrease mortality (RR= 0.93; 95% CI: 0.86--1.00) when administrated in a long time. It may indicate that calcium therapy does not increase risk of death \[[@B66]\]. Whether vitamin D given together with calcium is more beneficial than calcium alone treatment needs more RCTs to be clarified.

There is not sufficient evidence to draw conclusions of the effect of vitamin D on specific mortality with only 3 trials collected mortality data in a rigorous fashion. Vitamin D may have a beneficial effect on cancer related mortality. But it needs more RCTs to better understand the effect of vitamin D on cancer. Meta-analyses of cohort studies have suggested that vitamin D intake was associated with reduced risk of colorectal cancer \[[@B67]\], breast cancer \[[@B68]\] but not prostate cancer \[[@B69]\]. Vitamin D had no significant effect on cardiovascular disease mortality. A growing number of literature suggest that low levels of vitamin D are associated with cardiovascular disease risk \[[@B70]-[@B74]\]. A limited number of interventional studies that investigated the effects of vitamin D supplementation on cardiovascular disease risk showed mixed results \[[@B75]-[@B78]\]. The effect of vitamin D on cardiovascular diseases remains to be identified.

The mechanism of vitamin D benefit on overall mortality is not clear. Both forms of vitamin D (D~2~ and D~3~) are converted to 25-hydroxyvitamin \[25(OH)D\] in the liver, and then hydroxylated to 1,25-dihydroxyvitamin D in the kidney \[[@B79]\]. 1,25(OH)~2~D is the only biologically active form of vitamin D, which increases calcium absorption and bone formation to maintain bone health, regulate blood pressure and insulin production, prevent heart disease, regulate immune function to prevent diabetes and autoimmune disease, regulate cell growth to prevent cancer \[[@B80],[@B81]\].

Vitamin D insufficiency (\< 50 nmol/L) has now been linked to a broad spectrum of human diseases from cancer to cardiovascular to autoimmune conditions \[82\]. Though vitamin D can acquire through cutaneous synthesis after sunlight exposure and nutrition \[[@B83]\], it is often not sufficient to reach the required levels of vitamin D, especially in patients with osteoporosis and fracture risk \[84\]. In that case, supplementation of vitamin D is required, in order to prevent vitamin D insufficiency and associated adverse outcomes.

Similar to other meta-analyses, our review has several limitations. First, though extensive searches were made, there were no data of Hispanic or Orientals. Second, most of the participants in the present study were older women, the effects of vitamin D on mortality in younger, healthy persons and in males are still inconclusive. Third, the overall RR (95% CI) effect was modest and could be the result of chance alone. Fourth, there were only 13 trials that have durations of follow up longer than 3 years.

In conclusion, our results implicated that long-term supplementation of vitamin D may have a beneficial effect on overall mortality, especially in patients with vitamin D insufficiency and younger than 80 years. Vitamin D in a dose of 800 IU daily or less was found to be more favorable than a dose greater than 800 IU and treatment with cholecalciferol was more favorable than ergocalciferol. Future studies are needed to test the efficacy of vitamin D on specific mortality, such as cancer and cardiovascular disease mortality in a long-term treatment duration.
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